Incyte Corporation: cross-border access for the specialty portfolio

Quick orientation

Incyte Corporation is a US biopharmaceutical company headquartered in Wilmington, Delaware. Incyte's strategic focus is on hematology-oncology, dermatology, and inflammatory disease, with a deep franchise around JAK inhibitor biology built on the foundational asset Jakafi (ruxolitinib). The company trades on NASDAQ as INCY. FDA approval scale spans approximately a dozen marketed products including hematology, solid-tumor oncology, immune dermatology, and a growing portfolio of newer label expansions. Incyte's commercial discipline is global, and the company has built a strong direct presence in the US, Europe, Japan, and select Asia-Pacific markets while operating partnerships in other geographies.

Incyte portfolio in cross-border NPP scope

Jakafi (ruxolitinib) is an FDA-approved oral Janus kinase (JAK1/JAK2) inhibitor for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera in patients with inadequate response or intolerance to hydroxyurea, and steroid-refractory acute or chronic graft-versus-host disease. US list pricing is approximately US$15,000 per month at standard dosing. Oral dosing, twice daily.

Opzelura (ruxolitinib cream) is an FDA-approved topical JAK inhibitor for mild to moderate atopic dermatitis and nonsegmental vitiligo in patients twelve years of age and older. US list pricing is approximately US$2,000 per 60g tube. Topical application twice daily.

Pemazyre (pemigatinib) is an FDA-approved oral FGFR inhibitor for previously treated unresectable locally advanced or metastatic cholangiocarcinoma with FGFR2 fusion or other rearrangement, and for myeloid/lymphoid neoplasms with FGFR1 rearrangement.

Olumiant (baricitinib), partnered with Eli Lilly, is an FDA-approved oral JAK inhibitor for rheumatoid arthritis, alopecia areata, and other immune indications.

Monjuvi (tafasitamab-cxix) is an FDA-approved CD19-directed monoclonal antibody for relapsed or refractory diffuse large B-cell lymphoma in combination with lenalidomide. Minjuvi is the EU brand for the same product.

Zynyz (retifanlimab-dlwr) is an FDA-approved PD-1 inhibitor for metastatic or recurrent locally advanced Merkel cell carcinoma. Iclusig (ponatinib) is an FDA-approved BCR-ABL inhibitor for chronic myeloid leukemia.

Why patients route through cross-border NPP

The Incyte portfolio includes several rare-disease and biomarker-defined indications where cross-border NPP demand is consistently strong. Pemazyre for FGFR2-rearranged cholangiocarcinoma is a precision-medicine indication: cholangiocarcinoma is itself uncommon, FGFR2 fusion testing is not routine outside major centers, and confirmed-fusion patients in the GCC, India, and Southeast Asia frequently have no local pemigatinib supply. Zynyz for Merkel cell carcinoma serves an ultra-rare cancer population. Opzelura for vitiligo is a different demand profile - a global pediatric and adult dermatology population with substantial unmet need and limited local supply of the FDA-approved topical JAK inhibitor.

Jakafi for steroid-refractory graft-versus-host disease is a hematology niche where post-transplant patients with documented refractory disease seek cross-border supply when local availability is constrained. Patient profile is typically: confirmed indication-specific diagnosis with documentation (FGFR2 fusion report, Merkel cell biopsy, GVHD staging); preserved performance status appropriate to the therapy; and treating-physician prescription with documentation of prior lines of therapy where the indication requires.

Common cross-border destinations

The highest-frequency NPP destinations for Incyte products from US-approved inventory are India, the United Arab Emirates, Saudi Arabia, Turkey, and Egypt. Hematology, GI oncology, dermatology, and rare-cancer referral centers in Mumbai, Bangalore, Dubai, Abu Dhabi, Riyadh, Istanbul, and Cairo drive most inbound referrals.

Manufacturer engagement posture

Reserve Meds coordinates Incyte-sourced US commercial product through DSCSA-compliant US specialty distributors. We are not affiliated with Incyte Corporation. Our role is patient-facing coordination on behalf of named individual patients with a verified prescription. For Incyte medical affairs or US commercial teams interested in cross-border NPP pathways, our BD contact is [email protected].

What Reserve Meds provides

For each Incyte product request, Reserve Meds coordinates: prescription verification with the treating physician; biomarker or diagnostic documentation review (FGFR2 fusion for Pemazyre, Merkel pathology for Zynyz, GVHD staging for steroid-refractory Jakafi indications); DSCSA serialized chain-of-custody from Incyte through licensed US wholesalers to the named patient; cold-chain shipping (2 to 8 degrees C) for biologics including Monjuvi and Zynyz with temperature data-loggers; ambient shipping for oral products and topical Opzelura; destination-country regulatory documentation for Ministry of Health named-patient approvals and customs clearance; and a dedicated coordinator from prescription to delivery.

Clinical governance and prescription review

Every prescription for a product on this page is reviewed by a US-licensed pharmacist before dispensing. Reserve Meds does not substitute generic equivalents for branded specialty products without an explicit prescriber instruction, and we do not dispense any product whose chain-of-custody we cannot serialize back to the FDA-authorised manufacturer or its licensed wholesale partner. Our clinical review confirms indication-on-label appropriateness based on the documentation submitted by the treating physician, identifies any standard drug-drug interaction or contraindication concerns, and confirms that the requested dose, dosing schedule, and dosage form match the prescription. Where the prescription is unclear or where the indication on the prescription is off-label, our pharmacist contacts the prescriber directly. We do not provide medical advice to patients beyond drug-information counseling at dispensing.

Supply chain integrity

Supply integrity is the foundation of Reserve Meds operations. Every shipment carries a serialized DSCSA pedigree document confirming the chain of ownership from the FDA-registered manufacturer or its authorised distributor through a licensed US wholesale distributor to Reserve Meds and onward to the named patient. We do not source through parallel-import channels, third-country re-import, or unverified online wholesale markets. Cold-chain shipments are packed in qualified shippers with temperature data-loggers reading and logging temperature throughout the journey; data-logger reads are reviewed on arrival, and any out-of-specification excursion triggers our quality-hold protocol. For frozen products such as gene therapies and certain antibody-drug conjugates, we use validated frozen-shipper systems with dry-ice replenishment as required.

Destination-country regulatory pathways

Cross-border named patient access operates under jurisdiction-specific regulatory frameworks. In the United Arab Emirates, the Ministry of Health and Prevention (MOHAP) and Dubai Health Authority operate import-permit pathways for unregistered or restricted medicines on a named-patient basis. Saudi Arabia, Qatar, Kuwait, Bahrain, and Oman each operate analogous Ministry of Health named-patient frameworks with country-specific documentation requirements. India operates a personal-import pathway under the Drugs and Cosmetics Rules for quantities consistent with personal therapeutic use, typically up to three months supply per shipment. Turkey, Egypt, Jordan, Lebanon, and Morocco each operate distinct named-patient or import-permit pathways. Reserve Meds maintains current regulatory intelligence for each of these jurisdictions and prepares the documentation package required for each shipment.

What to expect through the coordination process

Patients beginning a request receive an initial coordinator contact within one business day of submission. The coordinator reviews the prescription, identifies the documentation required for the destination country, and provides an indicative cost range. Once required documents are uploaded - prescription, prescriber license verification, patient identification, and any indication-specific documentation such as genetic test results or biomarker reports - we issue a firm quote inclusive of product cost, packaging, shipping, regulatory documentation, and our coordination fee. Patients confirm acceptance of the firm quote before any sourcing or shipping is initiated, and Reserve Meds does not collect any deposit at intake. Once the firm quote is accepted and payment is received, the coordinator initiates sourcing through our licensed wholesale partners and prepares the destination-country regulatory package. Typical end-to-end timing from accepted quote to delivery is two to four weeks for ambient-shipped products and three to five weeks for cold-chain shipments, with variability driven by destination-country customs and regulatory turnaround times.

Not affiliated with the manufacturer

Reserve Meds is an independent operator of named patient program coordination. We are not a subsidiary, affiliate, authorised distributor, or licensed representative of any pharmaceutical manufacturer, and no statement on this page should be read as a partnership, endorsement, or representation by the named manufacturer. Trade names and product references on this page are used for informational purposes to identify the FDA-approved products that Reserve Meds coordinates through US specialty wholesale channels on behalf of named individual patients.

Privacy and data handling

Patient data submitted to Reserve Meds is handled under our HIPAA-aligned privacy policy and our destination-country data protection commitments. We minimise data collection to what is necessary for prescription verification, regulatory documentation, and shipping logistics. Patient identifiable information is shared with US wholesalers, destination-country regulatory authorities, and shipping carriers only as required to complete the coordination, and is not used for any marketing purpose.

Next step for patients

Patients with a treating-physician prescription for an Incyte product can begin a request now. Start an Opzelura request › Start a Zynyz request ›

Next step for Incyte teams

Incyte medical affairs or commercial teams interested in cross-border NPP coordination for non-US territories can reach our BD team at [email protected].

Reserved for you.